Targeting Allosteric Pockets of SARS-CoV-2 Main Protease Mpro

25 August 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Repurposing of antivirals is an attractive therapeutic option for the treatment of COVID-19. Mpro (also called 3CLpro) is a key protease of SARS-CoV-2 involved in viral replication, and is a promising drug target for testing the existing antivirals. A major challenge to test the efficacy of antivirals is the conformational plasticity of Mpro and its future mutation prone flexibility. To address this, we hereby propose combination therapy by drugging two specific additional pockets of Mpro probed in our studies. Long scale Molecular Dynamics (MD) simulations provide evidence of these additional sites being allosteric. Suitable choice of drugs in catalytic and allosteric pockets appear to be essential for combination therapy. Current study, based on docking and extensive set of MD simulations, finds the combination of Elbasvir, Glecaprevir, Ritonavir to be a viable candidate for further experimental drug testing/pharmacophore design for Mpro.

Keywords

SARS-CoV-2, Molecular Dynamics Simulations, Mproprotease, Elbasvir, Glecaprevir, Ritonavir, Allostery, Combination therapy, COVID-19

Supplementary materials

Title
Description
Actions
Title
Supporting Information-AM
Description
Actions
Title
Supporting Information-AM
Description
Actions
Title
Mpro-AM
Description
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.